We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Acceptability of a Dapivirine/Placebo Gel Administered Rectally to HIV-1 Seronegative Adults (MTN-026).
- Authors
Bauermeister, José A.; Tingler, Ryan C.; Dominguez, Clara; Dunne, Eileen F.; Hoesley, Craig; Ho, Ken; Johnson, Sherri; Lucas, Jonathan; Macagna, Nicole; Brown, Elizabeth; Gundacker, Holly; Peda, Melissa; Jacobson, Cindy E.; Kramzer, Lindsay; Singh, Devika; Dezzutti, Charlene S.; Ayudhya, Ratiya Pamela Kunjara Na; Marzinke, Mark A.; Piper, Jeanna; Devlin, Bríd
- Abstract
This study describes the acceptability of a rectal microbicide gel formulation using dapivirine (DPV) among men and women from two countries (United States and Thailand) participating in the Microbicide Trials Network-026 trial. We evaluated participants' acceptability of a rectal DPV/placebo gel as part of a Phase I trial (N = 26; 18 male, 8 female). Participants reported favorable acceptability of the study gel, with most participants reporting that they liked the gel the same (n = 14; 53.8%) or more (n = 11; 42.4%) than when they started the trial. Over half of participants noted that they would prefer the gel over condoms (n = 13; 50%) or that they liked condoms and the gel equally (n = 8; 30.8%). Side effects across products included leakage (n = 8; 30.8%), diarrhea (n = 4; 15.4%), or soiling (n = 1; 3.8%). The high acceptability of a rectal gel underscores its promise as a short-acting biomedical prevention, warranting future research for HIV prevention. Trial Registration: NCT03239483.
- Subjects
UNITED States; THAILAND; HIV prevention; RECTAL medication; HIV seronegativity; ANTI-HIV agents; DIARRHEA; ANTI-infective agents; RANDOMIZED controlled trials; NON-nucleoside reverse transcriptase inhibitors; PHARMACEUTICAL gels; STATISTICAL sampling; CONDOMS; HIV
- Publication
AIDS & Behavior, 2022, Vol 26, Issue 5, p1333
- ISSN
1090-7165
- Publication type
Article
- DOI
10.1007/s10461-021-03490-8